Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MORF-057 by Morphic Therapeutic for Crohn's Disease (Regional Enteritis): Likelihood of Approval
MORF-057 is under clinical development by Morphic Therapeutic and currently in Phase II for Crohn's Disease (Regional Enteritis). According to...
MORF-057 by Morphic Therapeutic for Ulcerative Colitis: Likelihood of Approval
MORF-057 is under clinical development by Morphic Therapeutic and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Morphic Holding's MORF-057?
MORF-057 is a small molecule commercialized by Morphic Holding, with a leading Phase II program in Ulcerative Colitis. According to...